Skip to Main Content

The Role of Resistant Starch in COVID-19 Infection

  • Study HIC#:2000027887
  • Last Updated:07/15/2021

This study is a multicenter randomized trial to evaluate the efficacy of administering a dietary supplement containing resistant starch to non-hospitalized COVID-19 positive subjects, The intervention will begin as soon as possible after subjects test positive for COVID-19 and continue for 14 days. Investigators hypothesize that short-term administration of a dietary supplement containing resistant starch has the potential to reduce rates of hospitalization and improve time to clinical recovery and symptoms in non-hospitalized COVID-19 positive patients.

  • Age19 years and older
  • GenderBoth
  • Start Date05/29/2020
  • End Date05/01/2021

Trial Purpose and Description

This study is a multicenter randomized trial to evaluate the efficacy of resistant potato starch in reducing rates of hospitalization and improving time to clinical recovery in currently non-hospitalized COVID-19 positive patients

Eligibility Criteria

Inclusion Criteria:

  • greater than 18 years of age
  • COVID-positive status
  • Being monitored in an outpatient setting at one of our study sites:
  • Yale New Haven Hospital (YNHH)
  • University of Michigan
  • University of Minnesota

Exclusion Criteria:

  • inflammatory bowel disease
  • history of gastric bypass surgery
  • active Clostridium difficile infection
  • active participation in another COVID-19 interventional trial
  • any physical or psychological condition that, in the opinion of the investigator, would pose unacceptable risk to the patient or raise concern that the patient would not comply with the protocol procedures.
  • Reported allergy to starch
  • Difficulty swallowing in order to prevent any aspiration risk
  • Currently taking any IL-6 inhibitors such as Tocilizumab for any disease condition

Principal Investigator


For more information about this study, contact the Help us Discover team on: